Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195662 | 0.84 | CYP4F2 (0.56) | CYP4F2CYP4A11ABCB11CYP1A2CYP3A4 | |
| SCHEMBL3084127 | 0.78 | CYP4F2 (0.43) | CYP4F2CYP4A11ABCB11CYP1A2CYP3A4 | |
| SCHEMBL27646166 | 0.78 | CYP4F2 (0.47) | CYP4F2CYP4A11ABCB11CYP1A2CYP3A4 | |
| SCHEMBL6078202 | 0.77 | CYP4F2 (0.31) | CYP4F2CYP4A11ABCB11CYP1A2CYP3A4 | |
| SCHEMBL28730460 | 0.77 | CYP4F2 (0.42) | CYP4F2CYP4A11ABCB11CYP1A2CYP3A4 | |
| SCHEMBL29048965 | 0.77 | CYP4F2 (0.40) | CYP4F2CYP4A11ABCB11CYP1A2CYP3A4 | |
| SCHEMBL15413024 | 0.76 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL28730462 | 0.75 | CYP4F2 (0.41) | CYP4F2CYP4A11ABCB11CYP1A2CYP3A4 | |
| SCHEMBL10094796 | 0.75 | CYP4F2 (0.38) | CYP4F2CYP4A11ABCB11CYP1A2CYP3A4 | |
| SCHEMBL445544 | 0.75 | DGAT1 (0.39) | CYP4F2CYP4A11ABCB11CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044085-B1 | PENEM PRODRUGS | PFIZER PROD INC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7795243-B2 | Penem prodrugs | PFIZER, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795243-B2 | Penem prodrugs | PFIZER, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795243-B2 | Penem prodrugs | PFIZER, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795244-B2 | Penem prodrugs | PFIZER INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795244-B2 | Penem prodrugs | PFIZER INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795244-B2 | Penem prodrugs | PFIZER INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2044085-A2 | PENEM PRODRUGS | Pfizer Products Incorporated (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20090042853-A1 | PENEM PRODRUGS | PFIZER INC | 2009-02-12 | — | — | US | disclosed |
| US-20090042853-A1 | PENEM PRODRUGS | PFIZER INC | 2009-02-12 | — | — | US | disclosed |
| US-20090042853-A1 | PENEM PRODRUGS | PFIZER INC | 2009-02-12 | — | — | US | disclosed |
| US-20080009474-A1 | PENEM PRODRUGS | PFIZER INC | 2008-01-10 | — | — | US | disclosed |
| US-20080009474-A1 | PENEM PRODRUGS | PFIZER INC | 2008-01-10 | — | — | US | disclosed |
| US-20080009474-A1 | PENEM PRODRUGS | PFIZER INC | 2008-01-10 | — | — | US | disclosed |
| WO-2008001212-A2 | PENEM PRODRUGS | PFIZER PRODUCTS INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008001212-A2 | PENEM PRODRUGS | PFIZER PRODUCTS INC. (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009474-A1 | PENEM PRODRUGS | PGM2, PGLS, PMM2 | CYP4F2 390/4885CYP4A11 309/4885ABCB11 275/4885 |
| US-20090042853-A1 | PENEM PRODRUGS | PGM2, PMM2, SI | CYP4F2 357/4885CYP4A11 278/4885ABCB11 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.